DNase I en es it fr

DNase I Brand names, DNase I Analogs

DNase I Brand Names Mixture

  • No information avaliable

DNase I Chemical_Formula


DNase I RX_link


DNase I fda sheet

DNase I msds (material safety sheet)

DNase I Synthesis Reference

No information avaliable

DNase I Molecular Weight


DNase I Melting Point

67 oC (Chan, H.K. et al., Pharm Res. 13:756-761 (1996))

DNase I H2O Solubility

No information avaliable

DNase I State


DNase I LogP


DNase I Dosage Forms


DNase I Indication

For treatment of cystic fibrosis

DNase I Pharmacology

Cystic fibrosis (CF) is a disease characterized by the retention of viscous purulent secretions in the airways. These thick secretions contribute both to reduced pulmonary function and to frequent pulmonary infection. Purulent pulmonary secretions contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to these infections. Pulmozyme hydrolyzes the DNA in sputum of CF patients and reduces sputum viscoelasticity.

DNase I Absorption

No information avaliable

DNase I side effects and Toxicity

No information avaliable

DNase I Patient Information


DNase I Organisms Affected

Humans and other mammals